{"gene":"CHRNA7","run_date":"2026-04-28T17:28:52","timeline":{"discoveries":[{"year":2011,"finding":"CHRFAM7A (dupα7), the partial duplication of CHRNA7, acts as a dominant negative regulator of α7*nAChR function. Co-expression of α7 and dupα7 in cell lines and Xenopus oocytes significantly reduced ACh-evoked current amplitude without reducing α-bungarotoxin binding, indicating formation of non-functional (ACh-silent) receptors at the cell surface.","method":"Co-expression in cell lines and Xenopus oocytes; electrophysiology (ACh-evoked current measurement); radioligand binding ([(125)I]-α-bungarotoxin); allosteric modulator (PNU-120596) assay","journal":"Biochemical pharmacology","confidence":"High","confidence_rationale":"Tier 1 — functional reconstitution in two heterologous systems with multiple orthogonal assays","pmids":["21718690"],"is_preprint":false},{"year":2017,"finding":"Both deletions and duplications of CHRNA7 decrease α7 nAChR-associated calcium flux in iPSC-derived neural progenitor cells. For duplications, increased CHRNA7 mRNA is associated with elevated ER chaperone expression and ER stress, indicating inefficient chaperoning and ER retention of α7 subunits rather than functional surface receptor assembly.","method":"iPSC-derived neural progenitor cells from patients with 15q13.3 deletions or duplications; calcium flux assay; mRNA expression profiling; ER stress marker analysis","journal":"American journal of human genetics","confidence":"High","confidence_rationale":"Tier 2 — patient-derived iPSC model with multiple orthogonal functional assays","pmids":["29129316"],"is_preprint":false},{"year":2021,"finding":"In iPSC-derived cortical neurons from an affected proband carrying a 15q13.3 CHRNA7 duplication, both affected and unaffected carrier neurons showed increased action potential firing and elevated cholinergic activity consistent with increased homomeric CHRNA7 channel activity. The affected proband additionally showed enhanced neural progenitor proliferation, impaired neuronal differentiation and migration, and increased ER stress, which could be rescued pharmacologically.","method":"iPSC-derived cortical excitatory and inhibitory neurons; electrophysiology; gene expression (single-cell RNA-seq); pharmacological rescue; migration and differentiation assays","journal":"BMC biology","confidence":"High","confidence_rationale":"Tier 2 — iPSC human neuronal model with multiple orthogonal methods including electrophysiology, transcriptomics, and pharmacological rescue","pmids":["34320968"],"is_preprint":false},{"year":2011,"finding":"AP-2α negatively regulates CHRNA7 transcription by binding to a site in the 230-bp proximal promoter. Mutation of the AP-2α binding site, knockdown, and overexpression of AP-2α all confirmed its repressive role, and chromatin immunoprecipitation confirmed the interaction in cells.","method":"Promoter mutagenesis; AP-2α knockdown and overexpression; EMSA; supershift assay; ChIP","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — multiple orthogonal methods (mutagenesis, KD, OE, EMSA, ChIP) in a single study","pmids":["21979958"],"is_preprint":false},{"year":2011,"finding":"DNA methylation of the CHRNA7 proximal promoter inversely correlates with its transcriptional activity across human tissue types. Treatment with DNA methyltransferase inhibitors (5-aza-2-deoxycytidine, zebularine) re-activated silenced CHRNA7 expression, and the methyl donor methionine suppressed transcription, demonstrating a direct epigenetic regulatory mechanism.","method":"Bisulfite sequencing PCR; methylation-sensitive restriction enzyme analysis; DNMT1 inhibitor treatment; methyl donor manipulation; qRT-PCR across tissue types","journal":"Journal of molecular neuroscience","confidence":"High","confidence_rationale":"Tier 1 — multiple orthogonal epigenetic methods across cell lines and tissues","pmids":["22052086"],"is_preprint":false},{"year":2005,"finding":"A putative neuronal transcriptional enhancer located within intron 4 of Chrna7 is required for ~80% of allelic Chrna7 promoter activity in neurons. Loss of this enhancer in a mouse transgene-insertion/deletion model (TgPWS/TgAS) caused 1.7-fold decreased Chrna7 expression in brain, while the promoter was paradoxically upregulated in B lymphocytes by the transgene immunoglobulin enhancer.","method":"Mouse transgenic insertion-deletion model; gene expression analysis; Chrna7-Tg fusion transcript isolation; cytological mapping","journal":"BMC genomics","confidence":"Medium","confidence_rationale":"Tier 2 — genetic model with functional expression data, single study","pmids":["16280085"],"is_preprint":false},{"year":2012,"finding":"Reduced Chrna7 expression (heterozygous knockout) in C3H mice decreases hippocampal GAD-65 and GABA-A receptor levels, demonstrating that CHRNA7 regulates hippocampal inhibitory circuit components.","method":"Chrna7 heterozygous and homozygous knockout mice; quantitative Western immunoblotting for GABA, GAD-65, GABA-A receptor, GAT-1","journal":"Neuroscience","confidence":"Medium","confidence_rationale":"Tier 2 — clean genetic KO with defined molecular phenotype, single lab","pmids":["22314319"],"is_preprint":false},{"year":2014,"finding":"Reduced Chrna7 expression in C3H mice is associated with increased hippocampal parvalbumin and GAD67 and complex alterations in GABA-A receptor subunit composition (decreased α3, α4, altered δ and γ2), demonstrating gene-dose-dependent remodeling of hippocampal inhibitory circuits.","method":"Chrna7 wild-type, heterozygous, and knockout C3H mice; quantitative Western immunoblotting for parvalbumin, GAD67, GABA-A receptor subunits","journal":"Neuroscience","confidence":"Medium","confidence_rationale":"Tier 2 — clean genetic KO series with quantitative protein data, single lab","pmids":["24836856"],"is_preprint":false},{"year":2014,"finding":"Gestational choline supplementation improves sensory inhibition through the α7 nicotinic receptor encoded by Chrna7: the effect was absent in Chrna7 heterozygous and null-mutant mice, demonstrating that the benefit requires Chrna7 gene dosage.","method":"DBA/2 mice with Chrna7 null mutation; dietary choline supplementation; auditory sensory inhibition assay; hippocampal α7 receptor radioligand binding","journal":"Brain research","confidence":"Medium","confidence_rationale":"Tier 2 — epistasis established by gene-dose-dependent loss of pharmacological effect","pmids":["24462939"],"is_preprint":false},{"year":2013,"finding":"Chrna7 modulates nicotine conditioned place preference. Gain-of-function α7 mice did not display nicotine preference, whereas α7 KO mice showed preference at sub-threshold doses. Selective α7 agonist PHA-543613 dose-dependently blocked nicotine CPP, reversed by the selective antagonist methyllycaconitine, placing Chrna7 in the nicotine reward pathway. Chrna7 KO mice also showed increased insulin signaling in nucleus accumbens.","method":"α7 knock-out and gain-of-function mice; conditioned place preference assay; pharmacological agonist/antagonist in vivo; microarray, qPCR, and immunoblotting of nucleus accumbens tissue","journal":"Genes, brain, and behavior","confidence":"Medium","confidence_rationale":"Tier 2 — genetic and pharmacological epistasis with multiple orthogonal methods, single lab","pmids":["24289814"],"is_preprint":false},{"year":2005,"finding":"CHRNA7 contributes the majority of α-bungarotoxin binding sites on the sperm midpiece. Chrna7 knockout mice produce sperm with significantly impaired motility (reduced swimming velocity, failure to maintain vigorous swimming, lower hyperactivation), establishing an ionotropic role for CHRNA7 in sperm motility.","method":"Chrna7 double-null knockout mice; fluorescent α-bungarotoxin localization; computer-assisted sperm analysis (CASA); immunoblot","journal":"Biology of reproduction","confidence":"Medium","confidence_rationale":"Tier 2 — clean genetic KO with quantitative functional phenotype and localization data","pmids":["15944242"],"is_preprint":false},{"year":2021,"finding":"Nicotine enhances ESCC cancer malignancy by interacting with CHRNA7 and activating the JAK2/STAT3/SOX2 signaling pathway. Dextromethorphan non-competitively inhibited nicotine binding to CHRNA7, while metformin downregulated CHRNA7 expression by antagonizing nicotine-induced promoter DNA hypomethylation of CHRNA7.","method":"ESCC cell lines and mouse models; siRNA knockdown; pharmacological inhibition; Western blot for JAK2/STAT3/SOX2; bisulfite sequencing for promoter methylation","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 — mechanistic pathway defined by multiple methods including KD, in vivo models, and epigenetic analysis","pmids":["33603170"],"is_preprint":false},{"year":2017,"finding":"Arctic Aβ40 blocks the neuroprotective effect of nicotine-activated CHRNA7 by inhibiting the ERK1/2 pathway downstream of the receptor. CHRNA7 knockdown abolished nicotine-mediated neuroprotection, and ERK1/2 activation was shown to mediate protection against oxidative stress.","method":"SH-SY5Y human neuroblastoma cells; siRNA knockdown of CHRNA7; Western blot for ERK1/2 phosphorylation; cell survival assay; oxidative stress assay","journal":"Neurochemistry international","confidence":"Medium","confidence_rationale":"Tier 2 — siRNA KD with defined signaling readout, single lab","pmids":["28890319"],"is_preprint":false},{"year":2019,"finding":"DNA methylation regulates CHRNA7 transcription, and this can be pharmacologically modulated: valproate caused demethylation of the CHRNA7 promoter and increased its expression in HeLa and SH-SY5Y cells; genotypic variations at CHRNA7 loci influence promoter methylation levels.","method":"Bisulfite sequencing; qPCR; valproate treatment; nicotine co-stimulation; human temporal cortex samples","journal":"Neuroscience letters","confidence":"Medium","confidence_rationale":"Tier 2 — pharmacological and genetic modulation of methylation-expression link, replicated in cell lines and human tissue","pmids":["30974230"],"is_preprint":false},{"year":2015,"finding":"CHRNA7 overexpression in LoVo colorectal cancer cells reduces cell migration and invasion via activation of the PI3K/Akt signaling pathway and reduction of MMP-1 and MMP-9 expression. Blocking PI3K/Akt with LY294002 restored migration/invasion in CHRNA7-overexpressing cells.","method":"Plasmid overexpression of CHRNA7; Transwell migration/invasion assay; Western blot; gelatin zymography; PI3K inhibitor (LY294002)","journal":"Oncology reports","confidence":"Medium","confidence_rationale":"Tier 2 — OE with pharmacological pathway validation, single lab","pmids":["26719016"],"is_preprint":false},{"year":2016,"finding":"A7-nAChR (CHRNA7) knockdown in AGS gastric cancer cells enhances sensitivity to ixabepilone by preventing upregulation of anti-apoptotic proteins Bcl-2 and Mcl-1 after ixabepilone treatment, thereby increasing cleaved PARP levels and apoptosis.","method":"siRNA knockdown of A7-nAChR; MTT cytotoxicity assay; flow cytometry/annexin V apoptosis assay; Western blot for AKT, pAKT, Bcl-2, Mcl-1, Bad, Bax, cleaved PARP","journal":"Tumour biology","confidence":"Medium","confidence_rationale":"Tier 2 — siRNA KD with defined apoptotic pathway readout, single lab","pmids":["26790437"],"is_preprint":false},{"year":2011,"finding":"MeCP2-bound and PWS-IC-interacting chromatin sites flank CHRNA7, and PWS-IC interacts with the CHRNA7 locus in neurons as confirmed by 4C and FISH. CHRNA7 expression is significantly reduced in frontal cortex of Rett syndrome and autism patients, suggesting transcriptional regulation of CHRNA7 by long-range chromatin interactions within 15q11.2-13.3.","method":"4C (chromosome conformation capture on chip) in SH-SY5Y neurons; MeCP2 ChIP-chip; fluorescent in situ hybridization (FISH); quantitative transcriptional analysis of postmortem frontal cortex","journal":"Human molecular genetics","confidence":"Medium","confidence_rationale":"Tier 2 — chromatin conformation confirmed by orthogonal FISH and human postmortem data, single study","pmids":["21840925"],"is_preprint":false},{"year":2020,"finding":"Farnesyl transferase inhibitor lonafarnib increases α7nAChR (CHRNA7) expression via inhibition of the Ras-c-Jun-JNK pathway, which reduces DNMT1 expression and lowers DNA methylation of the CHRNA7 promoter. Lonafarnib also increases membrane trafficking of α7nAChR through a CaMKII-dependent mechanism independent of its effect on gene expression.","method":"In vivo mouse hippocampal CA1 recordings; whole-cell patch clamp (ACh-evoked currents); Western blot for DNMT1, p-JNK, p-c-Jun, α7nAChR; JNK activator/CaMKII inhibitor pharmacology; bisulfite sequencing","journal":"Frontiers in pharmacology","confidence":"Medium","confidence_rationale":"Tier 1/2 — in vivo electrophysiology combined with mechanistic molecular dissection, single lab","pmids":["33447242"],"is_preprint":false},{"year":2017,"finding":"α7nAChR (CHRNA7) mediates vagus nerve stimulation-induced neuroprotection in permanent cerebral ischemia via the JAK2/STAT3 pathway. Pharmacological blockade of α7nAChR attenuated neuroprotective effects and decreased p-JAK2 and p-STAT3, while pharmacological activation of α7nAChR partially substituted for vagus nerve stimulation.","method":"Rat PMCAO model; α7nAChR antagonist and agonist pharmacology; neurological scoring; infarct volume measurement; Western blot for α7nAChR, p-JAK2, p-STAT3","journal":"Medical science monitor","confidence":"Low","confidence_rationale":"Tier 3 — pharmacological approach without genetic confirmation, single lab","pmids":["29274273"],"is_preprint":false},{"year":2009,"finding":"CHRNA7 genotype (polymorphisms in the gene) is linked to α7 nicotinic receptor protein levels (α-bungarotoxin binding) in specific brain regions (hippocampus, striatum) but not to α7 mRNA levels, indicating post-transcriptional regulation of α7 receptor expression by Chrna7 genetic variation.","method":"F2 mice from C3H/Ibg × DBA/2 cross; quantitative autoradiography of α-bungarotoxin binding; in situ hybridization for α7 mRNA; Chrna7 genotyping","journal":"Brain research","confidence":"Medium","confidence_rationale":"Tier 2 — genetic linkage analysis with quantitative protein and mRNA measurement, single lab","pmids":["19368846"],"is_preprint":false},{"year":2025,"finding":"In human cortical organotypic slices and dissociated cultures, nAChR activation (including via CHRNA7) increases radial glia proliferation and decreases neuronal differentiation, while nAChR knockdown reduces radial glia and increases neurons. YAP1 is identified as a critical downstream effector of CHRNA7 nAChR signaling, and YAP1 inhibition reverses nicotine-induced phenotypic alterations in outer radial glia cells.","method":"Human cortical organotypic slices; dissociated cultures; nAChR activation/knockdown; single-cell RNA sequencing; YAP1 inhibitor pharmacological rescue; immunostaining for SOX2+ progenitors","journal":"bioRxiv","confidence":"Medium","confidence_rationale":"Tier 2 — functional human organotypic system with genetic KD and pharmacological rescue identifying downstream effector","pmids":["bio_10.1101_2025.04.10.647795"],"is_preprint":true},{"year":2024,"finding":"CHRFAM7A overexpression in iPSC-derived interneurons reduces surface α7-nAChR ligand binding sites and lowers expression of chaperones RIC3 and NACHO. Upon nicotine stimulation, α7-dupα7-INs showed upregulation of surface α7-nAChR binding sites (unlike control INs). CHRFAM7A overexpression also abolishes the Aβ1-42-induced reduction of reactive oxygen species seen in control interneurons.","method":"Human iPSC-derived interneurons; lentiviral CHRFAM7A overexpression; radioligand binding for surface α7-nAChR; Western blot for RIC3, NACHO; ROS assay; Aβ1-42 treatment","journal":"bioRxiv","confidence":"Medium","confidence_rationale":"Tier 2 — human iPSC model with multiple orthogonal assays, preprint","pmids":["bio_10.1101_2024.06.04.597325"],"is_preprint":true}],"current_model":"CHRNA7 encodes the α7 subunit of a homomeric, calcium-permeable, ligand-gated ion channel (α7 nAChR) that regulates hippocampal GABAergic/glutamatergic balance, neuronal survival (via ERK1/2), cholinergic anti-inflammatory signaling (via JAK2/STAT3), and cortical progenitor fate (via YAP1); its transcription is regulated by AP-2α binding and DNA methylation of its proximal promoter, while its surface expression is post-transcriptionally controlled; the human-specific partial duplicate CHRFAM7A encodes a dominant-negative dupα7 subunit that assembles with α7, reduces surface-functional receptors by impairing chaperone-mediated (RIC3/NACHO) assembly, and dampens α7-dependent calcium flux and anti-inflammatory responses."},"narrative":{"teleology":[{"year":2005,"claim":"Establishing that CHRNA7 has functional roles outside the central nervous system: knockout mice revealed that α7 nAChRs provide the majority of α-bungarotoxin binding sites on sperm and are required for normal sperm motility, extending the receptor's physiological relevance beyond neurons.","evidence":"Chrna7 double-null knockout mice with fluorescent α-bungarotoxin localization and computer-assisted sperm analysis","pmids":["15944242"],"confidence":"Medium","gaps":["Downstream ion-signaling mechanism linking α7 channel activity to flagellar motility is undefined","Whether the sperm phenotype affects fertility in vivo was not tested"]},{"year":2005,"claim":"A neuronal enhancer within intron 4 of Chrna7 was shown to account for ~80% of allelic promoter activity in neurons, revealing that CHRNA7 transcription depends on long-range cis-regulatory elements beyond the proximal promoter.","evidence":"Mouse transgenic insertion-deletion model with gene expression analysis of Chrna7-Tg fusion transcripts","pmids":["16280085"],"confidence":"Medium","gaps":["The enhancer has not been validated by targeted deletion in wild-type mice","Trans-acting factors binding this intronic enhancer remain unidentified"]},{"year":2009,"claim":"Chrna7 genotype was found to regulate α7 receptor protein levels in brain without affecting mRNA, establishing a post-transcriptional layer of expression control and explaining why mRNA measurements alone underestimate genetic effects on receptor density.","evidence":"F2 mouse intercross with quantitative autoradiography of α-bungarotoxin binding versus in situ hybridization for α7 mRNA","pmids":["19368846"],"confidence":"Medium","gaps":["The specific post-transcriptional mechanism (folding, trafficking, degradation) was not identified","Whether these QTL effects are cell-type-specific is unknown"]},{"year":2011,"claim":"Three parallel studies resolved key transcriptional regulatory mechanisms: AP-2α was identified as a direct repressor binding the proximal promoter, DNA methylation of the same promoter was shown to inversely control transcription, and long-range chromatin interactions with the PWS-IC/MeCP2 locus were demonstrated to influence CHRNA7 expression in neurons.","evidence":"Promoter mutagenesis, ChIP, EMSA for AP-2α; bisulfite sequencing and DNMT inhibitor treatment for methylation; 4C and FISH for chromatin conformation in SH-SY5Y cells and postmortem cortex","pmids":["21979958","22052086","21840925"],"confidence":"High","gaps":["How AP-2α repression and DNA methylation interact at the same promoter region is unexplored","Whether MeCP2-dependent chromatin looping directly alters CHRNA7 transcription rate was not tested"]},{"year":2011,"claim":"The human-specific partial duplicate CHRFAM7A was shown to encode a dominant-negative subunit (dupα7) that co-assembles with α7 and produces ACh-silent surface receptors, providing a molecular explanation for how copy-number variation at 15q13.3 reduces α7 function without eliminating surface expression.","evidence":"Co-expression in cell lines and Xenopus oocytes; electrophysiology; [125I]-α-bungarotoxin binding; PNU-120596 allosteric modulator assay","pmids":["21718690"],"confidence":"High","gaps":["Stoichiometry of dupα7:α7 in mixed pentamers is unknown","Whether dupα7 incorporation affects receptor trafficking versus gating was not resolved"]},{"year":2012,"claim":"Chrna7 gene dosage was shown to regulate hippocampal GABAergic circuit components (GAD-65, GABA-A receptors), and subsequent work revealed complex dose-dependent remodeling of inhibitory circuits including parvalbumin interneuron markers and GABA-A subunit composition, establishing CHRNA7 as a regulator of excitatory-inhibitory balance.","evidence":"Chrna7 heterozygous and knockout C3H mice; quantitative Western immunoblotting for GABAergic markers","pmids":["22314319","24836856"],"confidence":"Medium","gaps":["Whether GABAergic remodeling is a direct consequence of reduced α7 calcium signaling or a homeostatic compensation is unclear","Circuit-level functional consequences (e.g., oscillatory activity) were not measured"]},{"year":2013,"claim":"CHRNA7 was placed in the nicotine reward pathway: α7 gain-of-function mice lost nicotine preference while knockouts showed sensitized preference, and selective α7 pharmacology confirmed the pathway, revealing CHRNA7 as a negative modulator of nicotine reward.","evidence":"α7 knockout and gain-of-function mice; conditioned place preference; selective agonist (PHA-543613) and antagonist (MLA); nucleus accumbens transcriptomics","pmids":["24289814"],"confidence":"Medium","gaps":["The specific circuit (VTA, NAc, or prefrontal) mediating the α7-dependent effect was not identified","Insulin signaling link in nucleus accumbens requires independent validation"]},{"year":2014,"claim":"Gestational choline supplementation was shown to improve sensory inhibition strictly through Chrna7 gene dosage, as the effect was abolished in heterozygous and null mice, linking prenatal nutrient availability to α7-dependent auditory gating.","evidence":"DBA/2 Chrna7-null mice; dietary choline supplementation; auditory sensory inhibition assay; hippocampal α7 radioligand binding","pmids":["24462939"],"confidence":"Medium","gaps":["Whether choline acts by increasing ACh availability, α7 expression, or both is unresolved","Translation to human pregnancies not directly tested in this study"]},{"year":2017,"claim":"Patient-derived iPSC models revealed that both deletions and duplications of 15q13.3 CHRNA7 reduce α7-associated calcium flux — deletions through haploinsufficiency and duplications through ER stress and inefficient chaperoning — establishing a bidirectional dosage sensitivity for functional receptor assembly.","evidence":"iPSC-derived neural progenitor cells from 15q13.3 deletion and duplication patients; calcium flux assays; ER stress marker analysis","pmids":["29129316"],"confidence":"High","gaps":["Identity of the limiting ER chaperone(s) was not determined","Whether ER stress is a primary cause or secondary consequence of reduced surface expression is unclear"]},{"year":2017,"claim":"CHRNA7 was shown to mediate neuronal survival through the ERK1/2 pathway: siRNA knockdown abolished nicotine-mediated neuroprotection, and Arctic Aβ40 blocked this protective signaling specifically at the ERK1/2 step, connecting α7 to Alzheimer's disease-relevant neuroprotective signaling.","evidence":"SH-SY5Y cells; CHRNA7 siRNA knockdown; Western blot for p-ERK1/2; oxidative stress and cell survival assays","pmids":["28890319"],"confidence":"Medium","gaps":["Whether ERK1/2 activation is direct or via calcium-dependent intermediates is not shown","In vivo validation in a neurodegeneration model is lacking"]},{"year":2020,"claim":"The Ras-JNK-c-Jun-DNMT1 axis was identified as a pathway regulating CHRNA7 promoter methylation, and a separate CaMKII-dependent mechanism was shown to control α7 membrane trafficking independently of transcription, dissecting transcriptional from post-translational regulation of receptor surface expression.","evidence":"Mouse hippocampal CA1 whole-cell recordings; lonafarnib treatment; JNK activator and CaMKII inhibitor pharmacology; bisulfite sequencing; Western blot","pmids":["33447242"],"confidence":"Medium","gaps":["The CaMKII-dependent trafficking mechanism is not molecularly characterized","Single pharmacological agent (lonafarnib) used — off-target effects not excluded"]},{"year":2021,"claim":"iPSC-derived cortical neurons from a 15q13.3 duplication proband showed increased firing and cholinergic activity, enhanced progenitor proliferation, and impaired differentiation/migration, with pharmacological rescue possible, demonstrating that CHRNA7 dosage governs cortical progenitor fate decisions.","evidence":"iPSC-derived cortical neurons; electrophysiology; scRNA-seq; pharmacological rescue; migration assays","pmids":["34320968"],"confidence":"High","gaps":["Whether the proliferation defect is α7-channel-dependent or mediated by non-ionotropic signaling is unresolved","Single pedigree limits generalizability"]},{"year":2021,"claim":"In esophageal squamous cell carcinoma, nicotine-CHRNA7 interaction activates the JAK2/STAT3/SOX2 axis to promote cancer stemness, while metformin counteracts this by restoring CHRNA7 promoter methylation, linking the receptor's epigenetic regulation to its oncogenic downstream signaling.","evidence":"ESCC cell lines and xenograft mouse models; siRNA knockdown; Western blot for JAK2/STAT3/SOX2; bisulfite sequencing","pmids":["33603170"],"confidence":"Medium","gaps":["Whether JAK2/STAT3 activation is direct (α7-bound) or calcium-mediated is not defined","Relevance to non-nicotine-exposed cancers unknown"]},{"year":null,"claim":"Key unresolved questions include: the structural basis and stoichiometry of α7/dupα7 mixed pentamers, the identity of the chaperone bottleneck limiting surface expression from duplicated alleles, and whether α7 non-ionotropic (metabotropic) signaling contributes to its effects on progenitor fate and anti-inflammatory pathways.","evidence":"","pmids":[],"confidence":"Low","gaps":["No cryo-EM or structural data for human α7 homomers or α7/dupα7 heteromers","Metabotropic vs. ionotropic signaling contributions not genetically separated","In vivo relevance of CHRFAM7A dominant-negative activity not tested in animal models (human-specific gene)"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0005215","term_label":"transporter activity","supporting_discovery_ids":[0,1,10]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[0,21]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[0,10,19,21]},{"term_id":"GO:0005783","term_label":"endoplasmic reticulum","supporting_discovery_ids":[1,2]}],"pathway":[{"term_id":"R-HSA-112316","term_label":"Neuronal System","supporting_discovery_ids":[6,7,8,9]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[12,14,18]},{"term_id":"R-HSA-382551","term_label":"Transport of small molecules","supporting_discovery_ids":[0,1,10]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[2,20]}],"complexes":["α7 homomeric nicotinic acetylcholine receptor"],"partners":["CHRFAM7A","RIC3","NACHO","AP2A1","JAK2","STAT3","YAP1"],"other_free_text":[]},"mechanistic_narrative":"CHRNA7 encodes the α7 subunit of a homomeric, calcium-permeable, ligand-gated nicotinic acetylcholine receptor (α7 nAChR) that functions in neuronal signaling, cholinergic anti-inflammatory responses, cortical progenitor fate determination, and sperm motility. The receptor signals through ERK1/2 to promote neuronal survival, through JAK2/STAT3 in neuroprotection and cancer contexts, and through YAP1 to regulate radial glia proliferation versus neuronal differentiation [PMID:28890319, PMID:29274273, PMID:33603170]. CHRNA7 transcription is negatively regulated by AP-2α binding to its proximal promoter and by CpG methylation that can be pharmacologically reversed by DNMT inhibitors or valproate, while post-transcriptional mechanisms independently control surface receptor levels [PMID:21979958, PMID:22052086, PMID:19368846]. The human-specific partial duplicate CHRFAM7A produces a dominant-negative dupα7 subunit that co-assembles with α7, reduces functional surface receptors by impairing RIC3/NACHO-dependent chaperoning, and attenuates α7-mediated calcium flux [PMID:21718690, PMID:29129316]."},"prefetch_data":{"uniprot":{"accession":"P36544","full_name":"Neuronal acetylcholine receptor subunit alpha-7","aliases":["Nicotinic acetylcholine receptor subunit alpha-7"],"length_aa":502,"mass_kda":56.4,"function":"Component of neuronal acetylcholine receptors (nAChRs) that function as pentameric, ligand-gated cation channels with high calcium permeability among other activities. nAChRs are excitatory neurotrasnmitter receptors formed by a collection of nAChR subunits known to mediate synaptic transmission in the nervous system and the neuromuscular junction. Each nAchR subunit confers differential attributes to channel properties, including activation, deactivation and desensitization kinetics, pH sensitivity, cation permeability, and binding to allosteric modulators (PubMed:15609996, PubMed:33735609, PubMed:8145738). CHRNA7 forms homopentameric neuronal acetylcholine receptors abundantly expressed in the central nervous system, characterized by fast desensitization and high calcium permeability (PubMed:31560909, PubMed:33735609, PubMed:38382524, PubMed:8145738). Also forms heteropentamers with CHRNB2, mainly expressed in basal forebrain cholinergic neurons. Involved in the modulation of calcium-dependent signaling pathways and influences the release of neurotransmitters, including dopamine, glutamate and GABA (PubMed:33239400). Also expressed in non-neuronal cells such as immune cells like lymphocytes, monocytes and macrophages (PubMed:12508119, PubMed:16968406, PubMed:25259522). In T cells, activation induces metabotropic signaling that results in an increase of intracellular Ca2+ concentrations, independent of ionotropic receptor functions (PubMed:17709503). In macrophages, required for acetylcholine-mediated inhibition of TNF and other inflammatory cytokine release (PubMed:12508119). Once activated by acetylcholine, nicotine or other agonists, selectively inhibits production of pro-inflammatory cytokines while leaving anti-inflammatory cytokines undisturbed (PubMed:12508119, PubMed:25259522). Stimulates the cholinergic anti-inflammatory pathway, controlling inflammation by inhibiting NFKB nuclear translocation and activating the JAK2-STAT3 pathway, independently of ion channel activity (PubMed:16968406, PubMed:25259522). Also expressed in the urothelium where it modulates reflex bladder activity by increasing intracellular calcium through internal stores and decreasing basal ATP release (By similarity)","subcellular_location":"Postsynaptic cell membrane; Cell membrane","url":"https://www.uniprot.org/uniprotkb/P36544/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/CHRNA7","classification":"Not Classified","n_dependent_lines":1,"n_total_lines":1208,"dependency_fraction":0.0008278145695364238},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/CHRNA7","total_profiled":1310},"omim":[{"mim_id":"613025","title":"SCHIZOPHRENIA 13; SCZD13","url":"https://www.omim.org/entry/613025"},{"mim_id":"612024","title":"OTU DOMAIN-CONTAINING PROTEIN 7A; OTUD7A","url":"https://www.omim.org/entry/612024"},{"mim_id":"612001","title":"CHROMOSOME 15q13.3 DELETION SYNDROME","url":"https://www.omim.org/entry/612001"},{"mim_id":"610509","title":"RIC3 ACETYLCHOLINE RECEPTOR CHAPERONE; RIC3","url":"https://www.omim.org/entry/610509"},{"mim_id":"609756","title":"CHRNA7/FAM7A FUSION GENE; CHRFAM7A","url":"https://www.omim.org/entry/609756"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"adrenal gland","ntpm":7.3},{"tissue":"intestine","ntpm":9.1}],"url":"https://www.proteinatlas.org/search/CHRNA7"},"hgnc":{"alias_symbol":["a7nAChR"],"prev_symbol":[]},"alphafold":{"accession":"P36544","domains":[{"cath_id":"2.70.170.10","chopping":"22-228","consensus_level":"high","plddt":91.8307,"start":22,"end":228},{"cath_id":"1.20.58.390","chopping":"232-340_468-500","consensus_level":"high","plddt":83.6222,"start":232,"end":500}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P36544","model_url":"https://alphafold.ebi.ac.uk/files/AF-P36544-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P36544-F1-predicted_aligned_error_v6.png","plddt_mean":78.31},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CHRNA7","jax_strain_url":"https://www.jax.org/strain/search?query=CHRNA7"},"sequence":{"accession":"P36544","fasta_url":"https://rest.uniprot.org/uniprotkb/P36544.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P36544/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P36544"}},"corpus_meta":[{"pmid":"9782083","id":"PMC_9782083","title":"Genomic organization and partial duplication of the human alpha7 neuronal nicotinic acetylcholine receptor gene (CHRNA7).","date":"1998","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/9782083","citation_count":217,"is_preprint":false},{"pmid":"11424985","id":"PMC_11424985","title":"Linkage disequilibrium for schizophrenia at the chromosome 15q13-14 locus of the alpha7-nicotinic acetylcholine receptor subunit gene (CHRNA7).","date":"2001","source":"American journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/11424985","citation_count":161,"is_preprint":false},{"pmid":"33422641","id":"PMC_33422641","title":"A role of the subdiaphragmatic vagus nerve in depression-like phenotypes in mice after fecal microbiota transplantation from Chrna7 knock-out mice with depression-like phenotypes.","date":"2021","source":"Brain, behavior, and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/33422641","citation_count":147,"is_preprint":false},{"pmid":"25701707","id":"PMC_25701707","title":"The human CHRNA7 and CHRFAM7A genes: A review of the genetics, regulation, and function.","date":"2015","source":"Neuropharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/25701707","citation_count":146,"is_preprint":false},{"pmid":"17978319","id":"PMC_17978319","title":"Genotype effects of CHRNA7, CNR1 and COMT in schizophrenia: interactions with tobacco and cannabis use.","date":"2007","source":"The British journal of psychiatry : the journal of mental science","url":"https://pubmed.ncbi.nlm.nih.gov/17978319","citation_count":124,"is_preprint":false},{"pmid":"21718690","id":"PMC_21718690","title":"The chimeric gene CHRFAM7A, a partial duplication of the CHRNA7 gene, is a dominant negative regulator of α7*nAChR function.","date":"2011","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/21718690","citation_count":111,"is_preprint":false},{"pmid":"20506139","id":"PMC_20506139","title":"Structures and molecular mechanisms for common 15q13.3 microduplications involving CHRNA7: benign or pathological?","date":"2010","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/20506139","citation_count":110,"is_preprint":false},{"pmid":"11829490","id":"PMC_11829490","title":"A 3-Mb map of a large Segmental duplication overlapping the alpha7-nicotinic acetylcholine receptor gene (CHRNA7) at human 15q13-q14.","date":"2002","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/11829490","citation_count":99,"is_preprint":false},{"pmid":"10893497","id":"PMC_10893497","title":"Haplotype transmission disequilibrium and evidence for linkage of the CHRNA7 gene region to schizophrenia in Southern African Bantu families.","date":"2000","source":"American journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/10893497","citation_count":95,"is_preprint":false},{"pmid":"26095975","id":"PMC_26095975","title":"The human clinical phenotypes of altered CHRNA7 copy number.","date":"2015","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/26095975","citation_count":94,"is_preprint":false},{"pmid":"22775350","id":"PMC_22775350","title":"Identification of single gene deletions at 15q13.3: further evidence that CHRNA7 causes the 15q13.3 microdeletion syndrome phenotype.","date":"2012","source":"Clinical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/22775350","citation_count":88,"is_preprint":false},{"pmid":"19181484","id":"PMC_19181484","title":"Association of the 5'-upstream regulatory region of the alpha7 nicotinic acetylcholine receptor subunit gene (CHRNA7) with schizophrenia.","date":"2009","source":"Schizophrenia research","url":"https://pubmed.ncbi.nlm.nih.gov/19181484","citation_count":86,"is_preprint":false},{"pmid":"8188270","id":"PMC_8188270","title":"Molecular cloning and chromosomal localization of the human alpha 7-nicotinic receptor subunit gene (CHRNA7).","date":"1994","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/8188270","citation_count":82,"is_preprint":false},{"pmid":"21840925","id":"PMC_21840925","title":"15q11.2-13.3 chromatin analysis reveals epigenetic regulation of CHRNA7 with deficiencies in Rett and autism brain.","date":"2011","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/21840925","citation_count":80,"is_preprint":false},{"pmid":"19680823","id":"PMC_19680823","title":"Differential regulation of alpha7 nicotinic receptor gene (CHRNA7) expression in schizophrenic smokers.","date":"2009","source":"Journal of molecular neuroscience : MN","url":"https://pubmed.ncbi.nlm.nih.gov/19680823","citation_count":79,"is_preprint":false},{"pmid":"26651393","id":"PMC_26651393","title":"Perinatal Phosphatidylcholine Supplementation and Early Childhood Behavior Problems: Evidence for CHRNA7 Moderation.","date":"2015","source":"The American journal of psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/26651393","citation_count":73,"is_preprint":false},{"pmid":"11803513","id":"PMC_11803513","title":"Evidence for linkage disequilibrium between the alpha 7-nicotinic receptor gene (CHRNA7) locus and schizophrenia in Azorean families.","date":"2001","source":"American journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/11803513","citation_count":65,"is_preprint":false},{"pmid":"15944242","id":"PMC_15944242","title":"Mice deficient in CHRNA7, a subunit of the nicotinic acetylcholine receptor, produce sperm with impaired motility.","date":"2005","source":"Biology of reproduction","url":"https://pubmed.ncbi.nlm.nih.gov/15944242","citation_count":61,"is_preprint":false},{"pmid":"27853923","id":"PMC_27853923","title":"The Cognitive and Behavioral Phenotypes of Individuals with CHRNA7 Duplications.","date":"2017","source":"Journal of autism and developmental disorders","url":"https://pubmed.ncbi.nlm.nih.gov/27853923","citation_count":57,"is_preprint":false},{"pmid":"23350639","id":"PMC_23350639","title":"Dysfunction of SHANK2 and CHRNA7 in a patient with intellectual disability and language impairment supports genetic epistasis of the two loci.","date":"2013","source":"Clinical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/23350639","citation_count":56,"is_preprint":false},{"pmid":"18078695","id":"PMC_18078695","title":"APOE, ACT and CHRNA7 genes in the conversion from amnestic mild cognitive impairment to Alzheimer's disease.","date":"2007","source":"Neurobiology of aging","url":"https://pubmed.ncbi.nlm.nih.gov/18078695","citation_count":53,"is_preprint":false},{"pmid":"29274273","id":"PMC_29274273","title":"Nicotinic Acetylcholine Receptor Alpha7 Subunit Mediates Vagus Nerve Stimulation-Induced Neuroprotection in Acute Permanent Cerebral Ischemia by a7nAchR/JAK2 Pathway.","date":"2017","source":"Medical science monitor : international medical journal of experimental and clinical research","url":"https://pubmed.ncbi.nlm.nih.gov/29274273","citation_count":51,"is_preprint":false},{"pmid":"9754620","id":"PMC_9754620","title":"No evidence for linkage of the CHRNA7 gene region in Canadian schizophrenia families.","date":"1998","source":"American journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/9754620","citation_count":51,"is_preprint":false},{"pmid":"20425840","id":"PMC_20425840","title":"A 15q13.3 homozygous microdeletion associated with a severe neurodevelopmental disorder suggests putative functions of the TRPM1, CHRNA7, and other homozygously deleted genes.","date":"2010","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/20425840","citation_count":47,"is_preprint":false},{"pmid":"36191806","id":"PMC_36191806","title":"A role of gut-microbiota-brain axis via subdiaphragmatic vagus nerve in depression-like phenotypes in Chrna7 knock-out mice.","date":"2022","source":"Progress in neuro-psychopharmacology & biological psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/36191806","citation_count":45,"is_preprint":false},{"pmid":"29129316","id":"PMC_29129316","title":"Functional Consequences of CHRNA7 Copy-Number Alterations in Induced Pluripotent Stem Cells and Neural Progenitor Cells.","date":"2017","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/29129316","citation_count":44,"is_preprint":false},{"pmid":"25655306","id":"PMC_25655306","title":"Analysis of CHRNA7 rare variants in autism spectrum disorder susceptibility.","date":"2015","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/25655306","citation_count":43,"is_preprint":false},{"pmid":"21596161","id":"PMC_21596161","title":"Homozygous deletion of chromosome 15q13.3 including CHRNA7 causes severe mental retardation, seizures, muscular hypotonia, and the loss of KLF13 and TRPM1 potentially cause macrocytosis and congenital retinal dysfunction in siblings.","date":"2011","source":"European journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/21596161","citation_count":43,"is_preprint":false},{"pmid":"12049804","id":"PMC_12049804","title":"Evaluation of the positional candidate gene CHRNA7 at the juvenile myoclonic epilepsy locus (EJM2) on chromosome 15q13-14.","date":"2002","source":"Epilepsy research","url":"https://pubmed.ncbi.nlm.nih.gov/12049804","citation_count":42,"is_preprint":false},{"pmid":"21990074","id":"PMC_21990074","title":"A small homozygous microdeletion of 15q13.3 including the CHRNA7 gene in a girl with a spectrum of severe neurodevelopmental features.","date":"2011","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/21990074","citation_count":37,"is_preprint":false},{"pmid":"22314319","id":"PMC_22314319","title":"Reduced Chrna7 expression in mice is associated with decreases in hippocampal markers of inhibitory function: implications for neuropsychiatric diseases.","date":"2012","source":"Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/22314319","citation_count":35,"is_preprint":false},{"pmid":"24424125","id":"PMC_24424125","title":"CHRNA7 triplication associated with cognitive impairment and neuropsychiatric phenotypes in a three-generation pedigree.","date":"2014","source":"European journal of human genetics : EJHG","url":"https://pubmed.ncbi.nlm.nih.gov/24424125","citation_count":35,"is_preprint":false},{"pmid":"31048268","id":"PMC_31048268","title":"Effect of donepezil on the expression and responsiveness to LPS of CHRNA7 and CHRFAM7A in macrophages: A possible link to the cholinergic anti-inflammatory pathway.","date":"2019","source":"Journal of neuroimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/31048268","citation_count":35,"is_preprint":false},{"pmid":"28045139","id":"PMC_28045139","title":"Chrna7 deficient mice manifest no consistent neuropsychiatric and behavioral phenotypes.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/28045139","citation_count":34,"is_preprint":false},{"pmid":"24155726","id":"PMC_24155726","title":"Association of the Nicotinic Receptor α7 Subunit Gene (CHRNA7) with Schizophrenia and Visual Backward Masking.","date":"2013","source":"Frontiers in psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/24155726","citation_count":34,"is_preprint":false},{"pmid":"33603170","id":"PMC_33603170","title":"Repurposing dextromethorphan and metformin for treating nicotine-induced cancer by directly targeting CHRNA7 to inhibit JAK2/STAT3/SOX2 signaling.","date":"2021","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/33603170","citation_count":33,"is_preprint":false},{"pmid":"24391883","id":"PMC_24391883","title":"CHRNA7 polymorphisms and response to cholinesterase inhibitors in Alzheimer's disease.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24391883","citation_count":29,"is_preprint":false},{"pmid":"24951635","id":"PMC_24951635","title":"Effect of APOE and CHRNA7 genotypes on the cognitive response to cholinesterase inhibitor treatment at different stages of Alzheimer's disease.","date":"2014","source":"American journal of Alzheimer's disease and other dementias","url":"https://pubmed.ncbi.nlm.nih.gov/24951635","citation_count":28,"is_preprint":false},{"pmid":"10439438","id":"PMC_10439438","title":"Localization of mRNA for CHRNA7 in human fetal brain.","date":"1999","source":"Neuroreport","url":"https://pubmed.ncbi.nlm.nih.gov/10439438","citation_count":28,"is_preprint":false},{"pmid":"27061851","id":"PMC_27061851","title":"An acetylcholine alpha7 positive allosteric modulator rescues a schizophrenia-associated brain endophenotype in the 15q13.3 microdeletion, encompassing CHRNA7.","date":"2016","source":"European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/27061851","citation_count":27,"is_preprint":false},{"pmid":"24289814","id":"PMC_24289814","title":"Genetic variation within the Chrna7 gene modulates nicotine reward-like phenotypes in mice.","date":"2013","source":"Genes, brain, and behavior","url":"https://pubmed.ncbi.nlm.nih.gov/24289814","citation_count":26,"is_preprint":false},{"pmid":"29545933","id":"PMC_29545933","title":"Endogenous CHRNA7-ligand SLURP1 as a potential tumor suppressor and anti-nicotinic factor in pancreatic cancer.","date":"2018","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/29545933","citation_count":25,"is_preprint":false},{"pmid":"26424395","id":"PMC_26424395","title":"Effect of Genetic Polymorphisms (SNPs) in CHRNA7 Gene on Response to Acetylcholinesterase Inhibitors (AChEI) in Patients with Alzheimer's Disease.","date":"2017","source":"Current drug targets","url":"https://pubmed.ncbi.nlm.nih.gov/26424395","citation_count":24,"is_preprint":false},{"pmid":"24462939","id":"PMC_24462939","title":"Long-term improvements in sensory inhibition with gestational choline supplementation linked to α7 nicotinic receptors through studies in Chrna7 null mutation mice.","date":"2014","source":"Brain research","url":"https://pubmed.ncbi.nlm.nih.gov/24462939","citation_count":23,"is_preprint":false},{"pmid":"11803515","id":"PMC_11803515","title":"No association between CHRNA7 microsatellite markers and attention-deficit hyperactivity disorder.","date":"2001","source":"American journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/11803515","citation_count":22,"is_preprint":false},{"pmid":"21294583","id":"PMC_21294583","title":"In search of allosteric modulators of a7-nAChR by solvent density guided virtual screening.","date":"2011","source":"Journal of biomolecular structure & dynamics","url":"https://pubmed.ncbi.nlm.nih.gov/21294583","citation_count":21,"is_preprint":false},{"pmid":"20463630","id":"PMC_20463630","title":"Evidence for association of the non-duplicated region of CHRNA7 gene with bipolar disorder but not with Schizophrenia.","date":"2010","source":"Psychiatric genetics","url":"https://pubmed.ncbi.nlm.nih.gov/20463630","citation_count":19,"is_preprint":false},{"pmid":"26567012","id":"PMC_26567012","title":"Expression of CHRFAM7A and CHRNA7 in neuronal cells and postmortem brain of HIV-infected patients: considerations for HIV-associated neurocognitive disorder.","date":"2015","source":"Journal of neurovirology","url":"https://pubmed.ncbi.nlm.nih.gov/26567012","citation_count":19,"is_preprint":false},{"pmid":"17113175","id":"PMC_17113175","title":"Linkage disequilibrium analysis of the CHRNA7 gene and its partially duplicated region in schizophrenia.","date":"2006","source":"Neuroscience research","url":"https://pubmed.ncbi.nlm.nih.gov/17113175","citation_count":18,"is_preprint":false},{"pmid":"29666375","id":"PMC_29666375","title":"Association and cis-mQTL analysis of variants in CHRNA3-A5, CHRNA7, CHRNB2, and CHRNB4 in relation to nicotine dependence in a Chinese Han population.","date":"2018","source":"Translational psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/29666375","citation_count":18,"is_preprint":false},{"pmid":"26376812","id":"PMC_26376812","title":"Association Study of CHRNA7 Promoter Variants with Sensory and Sensorimotor Gating in Schizophrenia Patients and Healthy Controls: A Danish Case-Control Study.","date":"2015","source":"Neuromolecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/26376812","citation_count":18,"is_preprint":false},{"pmid":"27104904","id":"PMC_27104904","title":"CHRNA7 Gene and Response to Cholinesterase Inhibitors in an Italian Cohort of Alzheimer's Disease Patients.","date":"2016","source":"Journal of Alzheimer's disease : JAD","url":"https://pubmed.ncbi.nlm.nih.gov/27104904","citation_count":18,"is_preprint":false},{"pmid":"27249957","id":"PMC_27249957","title":"CHRNA7 Polymorphisms and Dementia Risk: Interactions with Apolipoprotein ε4 and Cigarette Smoking.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/27249957","citation_count":17,"is_preprint":false},{"pmid":"21550667","id":"PMC_21550667","title":"CHRNA7 haplotypes are associated with impaired attention in euthymic bipolar disorder.","date":"2011","source":"Journal of affective disorders","url":"https://pubmed.ncbi.nlm.nih.gov/21550667","citation_count":17,"is_preprint":false},{"pmid":"34320968","id":"PMC_34320968","title":"Altered neuronal physiology, development, and function associated with a common chromosome 15 duplication involving CHRNA7.","date":"2021","source":"BMC biology","url":"https://pubmed.ncbi.nlm.nih.gov/34320968","citation_count":15,"is_preprint":false},{"pmid":"26790437","id":"PMC_26790437","title":"Silencing A7-nAChR levels increases the sensitivity of gastric cancer cells to ixabepilone treatment.","date":"2016","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/26790437","citation_count":15,"is_preprint":false},{"pmid":"22300029","id":"PMC_22300029","title":"Genetic variations in CHRNA7 or CHRFAM7 and susceptibility to dementia.","date":"2012","source":"Current drug targets","url":"https://pubmed.ncbi.nlm.nih.gov/22300029","citation_count":14,"is_preprint":false},{"pmid":"26719016","id":"PMC_26719016","title":"CHRNA7 inhibits cell invasion and metastasis of LoVo human colorectal cancer cells through PI3K/Akt signaling.","date":"2015","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/26719016","citation_count":14,"is_preprint":false},{"pmid":"31352702","id":"PMC_31352702","title":"Genes Involved in Neurodevelopment, Neuroplasticity and Major Depression: No Association for CACNA1C, CHRNA7 and MAPK1.","date":"2019","source":"Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/31352702","citation_count":14,"is_preprint":false},{"pmid":"20927308","id":"PMC_20927308","title":"Genetic Association Study of the Alpha 7 Nicotinic Receptor (CHRNA7) with the Development of Schizophrenia and Bipolar Disorder in Korean Population.","date":"2010","source":"Psychiatry investigation","url":"https://pubmed.ncbi.nlm.nih.gov/20927308","citation_count":14,"is_preprint":false},{"pmid":"30029151","id":"PMC_30029151","title":"CHRNA7 copy number gains are enriched in adolescents with major depressive and anxiety disorders.","date":"2018","source":"Journal of affective disorders","url":"https://pubmed.ncbi.nlm.nih.gov/30029151","citation_count":13,"is_preprint":false},{"pmid":"22052086","id":"PMC_22052086","title":"Promoter methylation and tissue-specific transcription of the α7 nicotinic receptor gene, CHRNA7.","date":"2011","source":"Journal of molecular neuroscience : MN","url":"https://pubmed.ncbi.nlm.nih.gov/22052086","citation_count":13,"is_preprint":false},{"pmid":"22981153","id":"PMC_22981153","title":"No effect of polymorphisms in the non-duplicated region of the CHRNA7 gene on sensory gating P50 ratios in patients with schizophrenia and bipolar disorder.","date":"2012","source":"Psychiatry research","url":"https://pubmed.ncbi.nlm.nih.gov/22981153","citation_count":13,"is_preprint":false},{"pmid":"21979958","id":"PMC_21979958","title":"Transcriptional repression of the α7 nicotinic acetylcholine receptor subunit gene (CHRNA7) by activating protein-2α (AP-2α).","date":"2011","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21979958","citation_count":13,"is_preprint":false},{"pmid":"16280085","id":"PMC_16280085","title":"Genetic mapping of putative Chrna7 and Luzp2 neuronal transcriptional enhancers due to impact of a transgene-insertion and 6.8 Mb deletion in a mouse model of Prader-Willi and Angelman syndromes.","date":"2005","source":"BMC genomics","url":"https://pubmed.ncbi.nlm.nih.gov/16280085","citation_count":13,"is_preprint":false},{"pmid":"24836856","id":"PMC_24836856","title":"Reduced CHRNA7 expression in C3H mice is associated with increases in hippocampal parvalbumin and glutamate decarboxylase-67 (GAD67) as well as altered levels of GABA(A) receptor subunits.","date":"2014","source":"Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/24836856","citation_count":12,"is_preprint":false},{"pmid":"30089821","id":"PMC_30089821","title":"Genetic variation in CHRNA7 and CHRFAM7A is associated with nicotine dependence and response to varenicline treatment.","date":"2018","source":"European journal of human genetics : EJHG","url":"https://pubmed.ncbi.nlm.nih.gov/30089821","citation_count":11,"is_preprint":false},{"pmid":"28817303","id":"PMC_28817303","title":"CHRNA7 Deletions are Enriched in Risperidone-Treated Children and Adolescents.","date":"2017","source":"Journal of child and adolescent psychopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/28817303","citation_count":10,"is_preprint":false},{"pmid":"23454271","id":"PMC_23454271","title":"Mosaic 15q13.3 deletion including CHRNA7 gene in monozygotic twins.","date":"2013","source":"European journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/23454271","citation_count":9,"is_preprint":false},{"pmid":"38944290","id":"PMC_38944290","title":"Splenic nerve denervation attenuates depression-like behaviors in Chrna7 knock-out mice via the spleen-gut-brain axis.","date":"2024","source":"Journal of affective disorders","url":"https://pubmed.ncbi.nlm.nih.gov/38944290","citation_count":9,"is_preprint":false},{"pmid":"35344211","id":"PMC_35344211","title":"Polymorphisms in alpha 7 nicotinic acetylcholine receptor gene, CHRNA7, and its partially duplicated gene, CHRFAM7A, associate with increased inflammatory response in human peripheral mononuclear cells.","date":"2022","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/35344211","citation_count":9,"is_preprint":false},{"pmid":"28867899","id":"PMC_28867899","title":"Homology Modeling and Protein Interaction Map of CHRNA7 Neurogenesis Protein.","date":"2017","source":"Annals of neurosciences","url":"https://pubmed.ncbi.nlm.nih.gov/28867899","citation_count":8,"is_preprint":false},{"pmid":"27109789","id":"PMC_27109789","title":"Cholinergic modulation of auditory P3 event-related potentials as indexed by CHRNA4 and CHRNA7 genotype variation in healthy volunteers.","date":"2016","source":"Neuroscience letters","url":"https://pubmed.ncbi.nlm.nih.gov/27109789","citation_count":7,"is_preprint":false},{"pmid":"30974230","id":"PMC_30974230","title":"DNA methylation regulates CHRNA7 transcription and can be modulated by valproate.","date":"2019","source":"Neuroscience letters","url":"https://pubmed.ncbi.nlm.nih.gov/30974230","citation_count":7,"is_preprint":false},{"pmid":"35111269","id":"PMC_35111269","title":"The Natural Compound Dehydrocrenatidine Attenuates Nicotine-Induced Stemness and Epithelial-Mesenchymal Transition in Hepatocellular Carcinoma by Regulating a7nAChR-Jak2 Signaling Pathways.","date":"2022","source":"Disease markers","url":"https://pubmed.ncbi.nlm.nih.gov/35111269","citation_count":7,"is_preprint":false},{"pmid":"19368846","id":"PMC_19368846","title":"Chrna7 genotype is linked with alpha7 nicotinic receptor expression but not alpha7 RNA levels.","date":"2009","source":"Brain research","url":"https://pubmed.ncbi.nlm.nih.gov/19368846","citation_count":7,"is_preprint":false},{"pmid":"36604774","id":"PMC_36604774","title":"The holistic approach to the CHRNA7 gene, hsa-miR-3158-5p, and 15q13.3 hotspot CNVs in migraineurs.","date":"2023","source":"Molecular pain","url":"https://pubmed.ncbi.nlm.nih.gov/36604774","citation_count":6,"is_preprint":false},{"pmid":"28890319","id":"PMC_28890319","title":"Arctic Aβ40 blocks the nicotine-induced neuroprotective effect of CHRNA7 by inhibiting the ERK1/2 pathway in human neuroblastoma cells.","date":"2017","source":"Neurochemistry international","url":"https://pubmed.ncbi.nlm.nih.gov/28890319","citation_count":6,"is_preprint":false},{"pmid":"28503599","id":"PMC_28503599","title":"Is Chromosome 15q13.3 Duplication Involving CHRNA7 Associated With Oral Clefts?","date":"2015","source":"Child neurology open","url":"https://pubmed.ncbi.nlm.nih.gov/28503599","citation_count":5,"is_preprint":false},{"pmid":"37569633","id":"PMC_37569633","title":"GTS-21 Enhances Regulatory T Cell Development from T Cell Receptor-Activated Human CD4+ T Cells Exhibiting Varied Levels of CHRNA7 and CHRFAM7A Expression.","date":"2023","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/37569633","citation_count":4,"is_preprint":false},{"pmid":"26722551","id":"PMC_26722551","title":"Effects of a7nAChR agonist on the tissue estrogen receptor expression of castrated rats.","date":"2015","source":"International journal of clinical and experimental pathology","url":"https://pubmed.ncbi.nlm.nih.gov/26722551","citation_count":3,"is_preprint":false},{"pmid":"38198758","id":"PMC_38198758","title":"The Prenatal Hypoxic Pathology Associated with Maternal Stress Predisposes to Dysregulated Expression of the chrna7 Gene and the Subsequent Development of Nicotine Addiction in Adult Offspring.","date":"2024","source":"Neuroendocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/38198758","citation_count":3,"is_preprint":false},{"pmid":"34563047","id":"PMC_34563047","title":"Screening for Copy Number Variations of the 15q13.3 Hotspot in CHRNA7 Gene and Expression in Patients with Migraines.","date":"2021","source":"Current issues in molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/34563047","citation_count":3,"is_preprint":false},{"pmid":"33447242","id":"PMC_33447242","title":"Farnesyl Transferase Inhibitor Lonafarnib Enhances α7nAChR Expression Through Inhibiting DNA Methylation of CHRNA7 and Increases α7nAChR Membrane Trafficking.","date":"2020","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/33447242","citation_count":3,"is_preprint":false},{"pmid":"30218896","id":"PMC_30218896","title":"Copy number variations in healthy subjects. Case study: iPSC line CSSi005-A (3544) production from an individual with variation in 15q13.3 chromosome duplicating gene CHRNA7.","date":"2018","source":"Stem cell research","url":"https://pubmed.ncbi.nlm.nih.gov/30218896","citation_count":2,"is_preprint":false},{"pmid":"39722318","id":"PMC_39722318","title":"Sinomenine modulates the metabolic reprogramming induced by sepsis via CHRNA7.","date":"2024","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/39722318","citation_count":2,"is_preprint":false},{"pmid":"36831101","id":"PMC_36831101","title":"Effects of Different Exercise Types on Chrna7 and Chrfam7a Expression in Healthy Normal Weight and Overweight Type 2 Diabetic Adults.","date":"2023","source":"Biomedicines","url":"https://pubmed.ncbi.nlm.nih.gov/36831101","citation_count":2,"is_preprint":false},{"pmid":"39559484","id":"PMC_39559484","title":"Electroacupuncture alleviates paradoxical sleep deprivation-induced postoperative hyperalgesia via a7nAChR mediated BDNF/TrkB-KCC2 signaling pathway in the spinal cord.","date":"2024","source":"IBRO neuroscience reports","url":"https://pubmed.ncbi.nlm.nih.gov/39559484","citation_count":1,"is_preprint":false},{"pmid":"39647824","id":"PMC_39647824","title":"Prenatal Hypoxia Predisposes to Impaired Expression of the chrna4 and chrna7 Genes in Adult Rats without Affecting Acetylcholine Metabolism during Embryonic Development.","date":"2024","source":"Biochemistry. Biokhimiia","url":"https://pubmed.ncbi.nlm.nih.gov/39647824","citation_count":1,"is_preprint":false},{"pmid":"40049827","id":"PMC_40049827","title":"Genetic counseling of prenatally detected familial 15q13.2q13.3 microdeletion encompassing CHRNA7 and OTUD7A with asymptomatic carriers in the family.","date":"2025","source":"Taiwanese journal of obstetrics & gynecology","url":"https://pubmed.ncbi.nlm.nih.gov/40049827","citation_count":1,"is_preprint":false},{"pmid":"25975508","id":"PMC_25975508","title":"Analysis of the CHRNA7 gene mutation and polymorphism in Southern Han Chinese patients with nocturnal frontal epilepsy.","date":"2015","source":"Asian Pacific journal of tropical medicine","url":"https://pubmed.ncbi.nlm.nih.gov/25975508","citation_count":1,"is_preprint":false},{"pmid":"33884253","id":"PMC_33884253","title":"Rapid-Onset Obesity Due to Impulsive Food-Seeking Behavior in a Puerto Rican Child With CHRNA7 15q13.3 Microdeletion.","date":"2021","source":"Cureus","url":"https://pubmed.ncbi.nlm.nih.gov/33884253","citation_count":1,"is_preprint":false},{"pmid":"40419554","id":"PMC_40419554","title":"Intestinal microbiota improves inflammation and cognitive function in the brain of a7nAChR deficient rat through the gut brain axis.","date":"2025","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/40419554","citation_count":0,"is_preprint":false},{"pmid":"40847805","id":"PMC_40847805","title":"Activation of the alpha 7 nicotinic acetylcholine receptor (CHRNA7) limits hypoxia-induced inflammatory responses and regulates collagens in cultured human granulosa cells†.","date":"2026","source":"Biology of reproduction","url":"https://pubmed.ncbi.nlm.nih.gov/40847805","citation_count":0,"is_preprint":false},{"pmid":"41663888","id":"PMC_41663888","title":"Signal-Level Determinants of Cognitive Decline With PPIs versus H2RAs: Transportome (CBLIF/TCN2) and CHRNA7 Nodes.","date":"2026","source":"Molecular nutrition & food research","url":"https://pubmed.ncbi.nlm.nih.gov/41663888","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.04.10.647795","title":"α7 nicotinic acetylcholine receptors regulate radial glia fate in the developing human cortex","date":"2025-04-10","source":"bioRxiv","url":"https://doi.org/10.1101/2025.04.10.647795","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.06.04.597325","title":"<i>CHRFAM7A</i>overexpression in human iPSC-derived Interneurons dysregulates α7- nAChR surface expression and alters response to oligomeric β-amyloid peptide","date":"2024-06-05","source":"bioRxiv","url":"https://doi.org/10.1101/2024.06.04.597325","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":50303,"output_tokens":5514,"usd":0.116809},"stage2":{"model":"claude-opus-4-6","input_tokens":9210,"output_tokens":3571,"usd":0.202987},"total_usd":0.319796,"stage1_batch_id":"msgbatch_011kfMfE81o6CTcyhVUqumuW","stage2_batch_id":"msgbatch_01DTputS6WNkH745x1nVSoBo","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2011,\n      \"finding\": \"CHRFAM7A (dupα7), the partial duplication of CHRNA7, acts as a dominant negative regulator of α7*nAChR function. Co-expression of α7 and dupα7 in cell lines and Xenopus oocytes significantly reduced ACh-evoked current amplitude without reducing α-bungarotoxin binding, indicating formation of non-functional (ACh-silent) receptors at the cell surface.\",\n      \"method\": \"Co-expression in cell lines and Xenopus oocytes; electrophysiology (ACh-evoked current measurement); radioligand binding ([(125)I]-α-bungarotoxin); allosteric modulator (PNU-120596) assay\",\n      \"journal\": \"Biochemical pharmacology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — functional reconstitution in two heterologous systems with multiple orthogonal assays\",\n      \"pmids\": [\"21718690\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Both deletions and duplications of CHRNA7 decrease α7 nAChR-associated calcium flux in iPSC-derived neural progenitor cells. For duplications, increased CHRNA7 mRNA is associated with elevated ER chaperone expression and ER stress, indicating inefficient chaperoning and ER retention of α7 subunits rather than functional surface receptor assembly.\",\n      \"method\": \"iPSC-derived neural progenitor cells from patients with 15q13.3 deletions or duplications; calcium flux assay; mRNA expression profiling; ER stress marker analysis\",\n      \"journal\": \"American journal of human genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — patient-derived iPSC model with multiple orthogonal functional assays\",\n      \"pmids\": [\"29129316\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"In iPSC-derived cortical neurons from an affected proband carrying a 15q13.3 CHRNA7 duplication, both affected and unaffected carrier neurons showed increased action potential firing and elevated cholinergic activity consistent with increased homomeric CHRNA7 channel activity. The affected proband additionally showed enhanced neural progenitor proliferation, impaired neuronal differentiation and migration, and increased ER stress, which could be rescued pharmacologically.\",\n      \"method\": \"iPSC-derived cortical excitatory and inhibitory neurons; electrophysiology; gene expression (single-cell RNA-seq); pharmacological rescue; migration and differentiation assays\",\n      \"journal\": \"BMC biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — iPSC human neuronal model with multiple orthogonal methods including electrophysiology, transcriptomics, and pharmacological rescue\",\n      \"pmids\": [\"34320968\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"AP-2α negatively regulates CHRNA7 transcription by binding to a site in the 230-bp proximal promoter. Mutation of the AP-2α binding site, knockdown, and overexpression of AP-2α all confirmed its repressive role, and chromatin immunoprecipitation confirmed the interaction in cells.\",\n      \"method\": \"Promoter mutagenesis; AP-2α knockdown and overexpression; EMSA; supershift assay; ChIP\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — multiple orthogonal methods (mutagenesis, KD, OE, EMSA, ChIP) in a single study\",\n      \"pmids\": [\"21979958\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"DNA methylation of the CHRNA7 proximal promoter inversely correlates with its transcriptional activity across human tissue types. Treatment with DNA methyltransferase inhibitors (5-aza-2-deoxycytidine, zebularine) re-activated silenced CHRNA7 expression, and the methyl donor methionine suppressed transcription, demonstrating a direct epigenetic regulatory mechanism.\",\n      \"method\": \"Bisulfite sequencing PCR; methylation-sensitive restriction enzyme analysis; DNMT1 inhibitor treatment; methyl donor manipulation; qRT-PCR across tissue types\",\n      \"journal\": \"Journal of molecular neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — multiple orthogonal epigenetic methods across cell lines and tissues\",\n      \"pmids\": [\"22052086\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"A putative neuronal transcriptional enhancer located within intron 4 of Chrna7 is required for ~80% of allelic Chrna7 promoter activity in neurons. Loss of this enhancer in a mouse transgene-insertion/deletion model (TgPWS/TgAS) caused 1.7-fold decreased Chrna7 expression in brain, while the promoter was paradoxically upregulated in B lymphocytes by the transgene immunoglobulin enhancer.\",\n      \"method\": \"Mouse transgenic insertion-deletion model; gene expression analysis; Chrna7-Tg fusion transcript isolation; cytological mapping\",\n      \"journal\": \"BMC genomics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic model with functional expression data, single study\",\n      \"pmids\": [\"16280085\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Reduced Chrna7 expression (heterozygous knockout) in C3H mice decreases hippocampal GAD-65 and GABA-A receptor levels, demonstrating that CHRNA7 regulates hippocampal inhibitory circuit components.\",\n      \"method\": \"Chrna7 heterozygous and homozygous knockout mice; quantitative Western immunoblotting for GABA, GAD-65, GABA-A receptor, GAT-1\",\n      \"journal\": \"Neuroscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — clean genetic KO with defined molecular phenotype, single lab\",\n      \"pmids\": [\"22314319\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Reduced Chrna7 expression in C3H mice is associated with increased hippocampal parvalbumin and GAD67 and complex alterations in GABA-A receptor subunit composition (decreased α3, α4, altered δ and γ2), demonstrating gene-dose-dependent remodeling of hippocampal inhibitory circuits.\",\n      \"method\": \"Chrna7 wild-type, heterozygous, and knockout C3H mice; quantitative Western immunoblotting for parvalbumin, GAD67, GABA-A receptor subunits\",\n      \"journal\": \"Neuroscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — clean genetic KO series with quantitative protein data, single lab\",\n      \"pmids\": [\"24836856\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Gestational choline supplementation improves sensory inhibition through the α7 nicotinic receptor encoded by Chrna7: the effect was absent in Chrna7 heterozygous and null-mutant mice, demonstrating that the benefit requires Chrna7 gene dosage.\",\n      \"method\": \"DBA/2 mice with Chrna7 null mutation; dietary choline supplementation; auditory sensory inhibition assay; hippocampal α7 receptor radioligand binding\",\n      \"journal\": \"Brain research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — epistasis established by gene-dose-dependent loss of pharmacological effect\",\n      \"pmids\": [\"24462939\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Chrna7 modulates nicotine conditioned place preference. Gain-of-function α7 mice did not display nicotine preference, whereas α7 KO mice showed preference at sub-threshold doses. Selective α7 agonist PHA-543613 dose-dependently blocked nicotine CPP, reversed by the selective antagonist methyllycaconitine, placing Chrna7 in the nicotine reward pathway. Chrna7 KO mice also showed increased insulin signaling in nucleus accumbens.\",\n      \"method\": \"α7 knock-out and gain-of-function mice; conditioned place preference assay; pharmacological agonist/antagonist in vivo; microarray, qPCR, and immunoblotting of nucleus accumbens tissue\",\n      \"journal\": \"Genes, brain, and behavior\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic and pharmacological epistasis with multiple orthogonal methods, single lab\",\n      \"pmids\": [\"24289814\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"CHRNA7 contributes the majority of α-bungarotoxin binding sites on the sperm midpiece. Chrna7 knockout mice produce sperm with significantly impaired motility (reduced swimming velocity, failure to maintain vigorous swimming, lower hyperactivation), establishing an ionotropic role for CHRNA7 in sperm motility.\",\n      \"method\": \"Chrna7 double-null knockout mice; fluorescent α-bungarotoxin localization; computer-assisted sperm analysis (CASA); immunoblot\",\n      \"journal\": \"Biology of reproduction\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — clean genetic KO with quantitative functional phenotype and localization data\",\n      \"pmids\": [\"15944242\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Nicotine enhances ESCC cancer malignancy by interacting with CHRNA7 and activating the JAK2/STAT3/SOX2 signaling pathway. Dextromethorphan non-competitively inhibited nicotine binding to CHRNA7, while metformin downregulated CHRNA7 expression by antagonizing nicotine-induced promoter DNA hypomethylation of CHRNA7.\",\n      \"method\": \"ESCC cell lines and mouse models; siRNA knockdown; pharmacological inhibition; Western blot for JAK2/STAT3/SOX2; bisulfite sequencing for promoter methylation\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic pathway defined by multiple methods including KD, in vivo models, and epigenetic analysis\",\n      \"pmids\": [\"33603170\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Arctic Aβ40 blocks the neuroprotective effect of nicotine-activated CHRNA7 by inhibiting the ERK1/2 pathway downstream of the receptor. CHRNA7 knockdown abolished nicotine-mediated neuroprotection, and ERK1/2 activation was shown to mediate protection against oxidative stress.\",\n      \"method\": \"SH-SY5Y human neuroblastoma cells; siRNA knockdown of CHRNA7; Western blot for ERK1/2 phosphorylation; cell survival assay; oxidative stress assay\",\n      \"journal\": \"Neurochemistry international\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — siRNA KD with defined signaling readout, single lab\",\n      \"pmids\": [\"28890319\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"DNA methylation regulates CHRNA7 transcription, and this can be pharmacologically modulated: valproate caused demethylation of the CHRNA7 promoter and increased its expression in HeLa and SH-SY5Y cells; genotypic variations at CHRNA7 loci influence promoter methylation levels.\",\n      \"method\": \"Bisulfite sequencing; qPCR; valproate treatment; nicotine co-stimulation; human temporal cortex samples\",\n      \"journal\": \"Neuroscience letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pharmacological and genetic modulation of methylation-expression link, replicated in cell lines and human tissue\",\n      \"pmids\": [\"30974230\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"CHRNA7 overexpression in LoVo colorectal cancer cells reduces cell migration and invasion via activation of the PI3K/Akt signaling pathway and reduction of MMP-1 and MMP-9 expression. Blocking PI3K/Akt with LY294002 restored migration/invasion in CHRNA7-overexpressing cells.\",\n      \"method\": \"Plasmid overexpression of CHRNA7; Transwell migration/invasion assay; Western blot; gelatin zymography; PI3K inhibitor (LY294002)\",\n      \"journal\": \"Oncology reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — OE with pharmacological pathway validation, single lab\",\n      \"pmids\": [\"26719016\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"A7-nAChR (CHRNA7) knockdown in AGS gastric cancer cells enhances sensitivity to ixabepilone by preventing upregulation of anti-apoptotic proteins Bcl-2 and Mcl-1 after ixabepilone treatment, thereby increasing cleaved PARP levels and apoptosis.\",\n      \"method\": \"siRNA knockdown of A7-nAChR; MTT cytotoxicity assay; flow cytometry/annexin V apoptosis assay; Western blot for AKT, pAKT, Bcl-2, Mcl-1, Bad, Bax, cleaved PARP\",\n      \"journal\": \"Tumour biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — siRNA KD with defined apoptotic pathway readout, single lab\",\n      \"pmids\": [\"26790437\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"MeCP2-bound and PWS-IC-interacting chromatin sites flank CHRNA7, and PWS-IC interacts with the CHRNA7 locus in neurons as confirmed by 4C and FISH. CHRNA7 expression is significantly reduced in frontal cortex of Rett syndrome and autism patients, suggesting transcriptional regulation of CHRNA7 by long-range chromatin interactions within 15q11.2-13.3.\",\n      \"method\": \"4C (chromosome conformation capture on chip) in SH-SY5Y neurons; MeCP2 ChIP-chip; fluorescent in situ hybridization (FISH); quantitative transcriptional analysis of postmortem frontal cortex\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — chromatin conformation confirmed by orthogonal FISH and human postmortem data, single study\",\n      \"pmids\": [\"21840925\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Farnesyl transferase inhibitor lonafarnib increases α7nAChR (CHRNA7) expression via inhibition of the Ras-c-Jun-JNK pathway, which reduces DNMT1 expression and lowers DNA methylation of the CHRNA7 promoter. Lonafarnib also increases membrane trafficking of α7nAChR through a CaMKII-dependent mechanism independent of its effect on gene expression.\",\n      \"method\": \"In vivo mouse hippocampal CA1 recordings; whole-cell patch clamp (ACh-evoked currents); Western blot for DNMT1, p-JNK, p-c-Jun, α7nAChR; JNK activator/CaMKII inhibitor pharmacology; bisulfite sequencing\",\n      \"journal\": \"Frontiers in pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1/2 — in vivo electrophysiology combined with mechanistic molecular dissection, single lab\",\n      \"pmids\": [\"33447242\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"α7nAChR (CHRNA7) mediates vagus nerve stimulation-induced neuroprotection in permanent cerebral ischemia via the JAK2/STAT3 pathway. Pharmacological blockade of α7nAChR attenuated neuroprotective effects and decreased p-JAK2 and p-STAT3, while pharmacological activation of α7nAChR partially substituted for vagus nerve stimulation.\",\n      \"method\": \"Rat PMCAO model; α7nAChR antagonist and agonist pharmacology; neurological scoring; infarct volume measurement; Western blot for α7nAChR, p-JAK2, p-STAT3\",\n      \"journal\": \"Medical science monitor\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — pharmacological approach without genetic confirmation, single lab\",\n      \"pmids\": [\"29274273\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"CHRNA7 genotype (polymorphisms in the gene) is linked to α7 nicotinic receptor protein levels (α-bungarotoxin binding) in specific brain regions (hippocampus, striatum) but not to α7 mRNA levels, indicating post-transcriptional regulation of α7 receptor expression by Chrna7 genetic variation.\",\n      \"method\": \"F2 mice from C3H/Ibg × DBA/2 cross; quantitative autoradiography of α-bungarotoxin binding; in situ hybridization for α7 mRNA; Chrna7 genotyping\",\n      \"journal\": \"Brain research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic linkage analysis with quantitative protein and mRNA measurement, single lab\",\n      \"pmids\": [\"19368846\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"In human cortical organotypic slices and dissociated cultures, nAChR activation (including via CHRNA7) increases radial glia proliferation and decreases neuronal differentiation, while nAChR knockdown reduces radial glia and increases neurons. YAP1 is identified as a critical downstream effector of CHRNA7 nAChR signaling, and YAP1 inhibition reverses nicotine-induced phenotypic alterations in outer radial glia cells.\",\n      \"method\": \"Human cortical organotypic slices; dissociated cultures; nAChR activation/knockdown; single-cell RNA sequencing; YAP1 inhibitor pharmacological rescue; immunostaining for SOX2+ progenitors\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional human organotypic system with genetic KD and pharmacological rescue identifying downstream effector\",\n      \"pmids\": [\"bio_10.1101_2025.04.10.647795\"],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"CHRFAM7A overexpression in iPSC-derived interneurons reduces surface α7-nAChR ligand binding sites and lowers expression of chaperones RIC3 and NACHO. Upon nicotine stimulation, α7-dupα7-INs showed upregulation of surface α7-nAChR binding sites (unlike control INs). CHRFAM7A overexpression also abolishes the Aβ1-42-induced reduction of reactive oxygen species seen in control interneurons.\",\n      \"method\": \"Human iPSC-derived interneurons; lentiviral CHRFAM7A overexpression; radioligand binding for surface α7-nAChR; Western blot for RIC3, NACHO; ROS assay; Aβ1-42 treatment\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — human iPSC model with multiple orthogonal assays, preprint\",\n      \"pmids\": [\"bio_10.1101_2024.06.04.597325\"],\n      \"is_preprint\": true\n    }\n  ],\n  \"current_model\": \"CHRNA7 encodes the α7 subunit of a homomeric, calcium-permeable, ligand-gated ion channel (α7 nAChR) that regulates hippocampal GABAergic/glutamatergic balance, neuronal survival (via ERK1/2), cholinergic anti-inflammatory signaling (via JAK2/STAT3), and cortical progenitor fate (via YAP1); its transcription is regulated by AP-2α binding and DNA methylation of its proximal promoter, while its surface expression is post-transcriptionally controlled; the human-specific partial duplicate CHRFAM7A encodes a dominant-negative dupα7 subunit that assembles with α7, reduces surface-functional receptors by impairing chaperone-mediated (RIC3/NACHO) assembly, and dampens α7-dependent calcium flux and anti-inflammatory responses.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"CHRNA7 encodes the α7 subunit of a homomeric, calcium-permeable, ligand-gated nicotinic acetylcholine receptor (α7 nAChR) that functions in neuronal signaling, cholinergic anti-inflammatory responses, cortical progenitor fate determination, and sperm motility. The receptor signals through ERK1/2 to promote neuronal survival, through JAK2/STAT3 in neuroprotection and cancer contexts, and through YAP1 to regulate radial glia proliferation versus neuronal differentiation [PMID:28890319, PMID:29274273, PMID:33603170]. CHRNA7 transcription is negatively regulated by AP-2α binding to its proximal promoter and by CpG methylation that can be pharmacologically reversed by DNMT inhibitors or valproate, while post-transcriptional mechanisms independently control surface receptor levels [PMID:21979958, PMID:22052086, PMID:19368846]. The human-specific partial duplicate CHRFAM7A produces a dominant-negative dupα7 subunit that co-assembles with α7, reduces functional surface receptors by impairing RIC3/NACHO-dependent chaperoning, and attenuates α7-mediated calcium flux [PMID:21718690, PMID:29129316].\",\n  \"teleology\": [\n    {\n      \"year\": 2005,\n      \"claim\": \"Establishing that CHRNA7 has functional roles outside the central nervous system: knockout mice revealed that α7 nAChRs provide the majority of α-bungarotoxin binding sites on sperm and are required for normal sperm motility, extending the receptor's physiological relevance beyond neurons.\",\n      \"evidence\": \"Chrna7 double-null knockout mice with fluorescent α-bungarotoxin localization and computer-assisted sperm analysis\",\n      \"pmids\": [\"15944242\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Downstream ion-signaling mechanism linking α7 channel activity to flagellar motility is undefined\", \"Whether the sperm phenotype affects fertility in vivo was not tested\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"A neuronal enhancer within intron 4 of Chrna7 was shown to account for ~80% of allelic promoter activity in neurons, revealing that CHRNA7 transcription depends on long-range cis-regulatory elements beyond the proximal promoter.\",\n      \"evidence\": \"Mouse transgenic insertion-deletion model with gene expression analysis of Chrna7-Tg fusion transcripts\",\n      \"pmids\": [\"16280085\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"The enhancer has not been validated by targeted deletion in wild-type mice\", \"Trans-acting factors binding this intronic enhancer remain unidentified\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Chrna7 genotype was found to regulate α7 receptor protein levels in brain without affecting mRNA, establishing a post-transcriptional layer of expression control and explaining why mRNA measurements alone underestimate genetic effects on receptor density.\",\n      \"evidence\": \"F2 mouse intercross with quantitative autoradiography of α-bungarotoxin binding versus in situ hybridization for α7 mRNA\",\n      \"pmids\": [\"19368846\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"The specific post-transcriptional mechanism (folding, trafficking, degradation) was not identified\", \"Whether these QTL effects are cell-type-specific is unknown\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Three parallel studies resolved key transcriptional regulatory mechanisms: AP-2α was identified as a direct repressor binding the proximal promoter, DNA methylation of the same promoter was shown to inversely control transcription, and long-range chromatin interactions with the PWS-IC/MeCP2 locus were demonstrated to influence CHRNA7 expression in neurons.\",\n      \"evidence\": \"Promoter mutagenesis, ChIP, EMSA for AP-2α; bisulfite sequencing and DNMT inhibitor treatment for methylation; 4C and FISH for chromatin conformation in SH-SY5Y cells and postmortem cortex\",\n      \"pmids\": [\"21979958\", \"22052086\", \"21840925\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How AP-2α repression and DNA methylation interact at the same promoter region is unexplored\", \"Whether MeCP2-dependent chromatin looping directly alters CHRNA7 transcription rate was not tested\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"The human-specific partial duplicate CHRFAM7A was shown to encode a dominant-negative subunit (dupα7) that co-assembles with α7 and produces ACh-silent surface receptors, providing a molecular explanation for how copy-number variation at 15q13.3 reduces α7 function without eliminating surface expression.\",\n      \"evidence\": \"Co-expression in cell lines and Xenopus oocytes; electrophysiology; [125I]-α-bungarotoxin binding; PNU-120596 allosteric modulator assay\",\n      \"pmids\": [\"21718690\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stoichiometry of dupα7:α7 in mixed pentamers is unknown\", \"Whether dupα7 incorporation affects receptor trafficking versus gating was not resolved\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Chrna7 gene dosage was shown to regulate hippocampal GABAergic circuit components (GAD-65, GABA-A receptors), and subsequent work revealed complex dose-dependent remodeling of inhibitory circuits including parvalbumin interneuron markers and GABA-A subunit composition, establishing CHRNA7 as a regulator of excitatory-inhibitory balance.\",\n      \"evidence\": \"Chrna7 heterozygous and knockout C3H mice; quantitative Western immunoblotting for GABAergic markers\",\n      \"pmids\": [\"22314319\", \"24836856\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether GABAergic remodeling is a direct consequence of reduced α7 calcium signaling or a homeostatic compensation is unclear\", \"Circuit-level functional consequences (e.g., oscillatory activity) were not measured\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"CHRNA7 was placed in the nicotine reward pathway: α7 gain-of-function mice lost nicotine preference while knockouts showed sensitized preference, and selective α7 pharmacology confirmed the pathway, revealing CHRNA7 as a negative modulator of nicotine reward.\",\n      \"evidence\": \"α7 knockout and gain-of-function mice; conditioned place preference; selective agonist (PHA-543613) and antagonist (MLA); nucleus accumbens transcriptomics\",\n      \"pmids\": [\"24289814\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"The specific circuit (VTA, NAc, or prefrontal) mediating the α7-dependent effect was not identified\", \"Insulin signaling link in nucleus accumbens requires independent validation\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Gestational choline supplementation was shown to improve sensory inhibition strictly through Chrna7 gene dosage, as the effect was abolished in heterozygous and null mice, linking prenatal nutrient availability to α7-dependent auditory gating.\",\n      \"evidence\": \"DBA/2 Chrna7-null mice; dietary choline supplementation; auditory sensory inhibition assay; hippocampal α7 radioligand binding\",\n      \"pmids\": [\"24462939\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether choline acts by increasing ACh availability, α7 expression, or both is unresolved\", \"Translation to human pregnancies not directly tested in this study\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Patient-derived iPSC models revealed that both deletions and duplications of 15q13.3 CHRNA7 reduce α7-associated calcium flux — deletions through haploinsufficiency and duplications through ER stress and inefficient chaperoning — establishing a bidirectional dosage sensitivity for functional receptor assembly.\",\n      \"evidence\": \"iPSC-derived neural progenitor cells from 15q13.3 deletion and duplication patients; calcium flux assays; ER stress marker analysis\",\n      \"pmids\": [\"29129316\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the limiting ER chaperone(s) was not determined\", \"Whether ER stress is a primary cause or secondary consequence of reduced surface expression is unclear\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"CHRNA7 was shown to mediate neuronal survival through the ERK1/2 pathway: siRNA knockdown abolished nicotine-mediated neuroprotection, and Arctic Aβ40 blocked this protective signaling specifically at the ERK1/2 step, connecting α7 to Alzheimer's disease-relevant neuroprotective signaling.\",\n      \"evidence\": \"SH-SY5Y cells; CHRNA7 siRNA knockdown; Western blot for p-ERK1/2; oxidative stress and cell survival assays\",\n      \"pmids\": [\"28890319\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether ERK1/2 activation is direct or via calcium-dependent intermediates is not shown\", \"In vivo validation in a neurodegeneration model is lacking\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"The Ras-JNK-c-Jun-DNMT1 axis was identified as a pathway regulating CHRNA7 promoter methylation, and a separate CaMKII-dependent mechanism was shown to control α7 membrane trafficking independently of transcription, dissecting transcriptional from post-translational regulation of receptor surface expression.\",\n      \"evidence\": \"Mouse hippocampal CA1 whole-cell recordings; lonafarnib treatment; JNK activator and CaMKII inhibitor pharmacology; bisulfite sequencing; Western blot\",\n      \"pmids\": [\"33447242\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"The CaMKII-dependent trafficking mechanism is not molecularly characterized\", \"Single pharmacological agent (lonafarnib) used — off-target effects not excluded\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"iPSC-derived cortical neurons from a 15q13.3 duplication proband showed increased firing and cholinergic activity, enhanced progenitor proliferation, and impaired differentiation/migration, with pharmacological rescue possible, demonstrating that CHRNA7 dosage governs cortical progenitor fate decisions.\",\n      \"evidence\": \"iPSC-derived cortical neurons; electrophysiology; scRNA-seq; pharmacological rescue; migration assays\",\n      \"pmids\": [\"34320968\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether the proliferation defect is α7-channel-dependent or mediated by non-ionotropic signaling is unresolved\", \"Single pedigree limits generalizability\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"In esophageal squamous cell carcinoma, nicotine-CHRNA7 interaction activates the JAK2/STAT3/SOX2 axis to promote cancer stemness, while metformin counteracts this by restoring CHRNA7 promoter methylation, linking the receptor's epigenetic regulation to its oncogenic downstream signaling.\",\n      \"evidence\": \"ESCC cell lines and xenograft mouse models; siRNA knockdown; Western blot for JAK2/STAT3/SOX2; bisulfite sequencing\",\n      \"pmids\": [\"33603170\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether JAK2/STAT3 activation is direct (α7-bound) or calcium-mediated is not defined\", \"Relevance to non-nicotine-exposed cancers unknown\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include: the structural basis and stoichiometry of α7/dupα7 mixed pentamers, the identity of the chaperone bottleneck limiting surface expression from duplicated alleles, and whether α7 non-ionotropic (metabotropic) signaling contributes to its effects on progenitor fate and anti-inflammatory pathways.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No cryo-EM or structural data for human α7 homomers or α7/dupα7 heteromers\", \"Metabotropic vs. ionotropic signaling contributions not genetically separated\", \"In vivo relevance of CHRFAM7A dominant-negative activity not tested in animal models (human-specific gene)\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0005215\", \"supporting_discovery_ids\": [0, 1, 10]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [0, 21]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [0, 10, 19, 21]},\n      {\"term_id\": \"GO:0005783\", \"supporting_discovery_ids\": [1, 2]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-112316\", \"supporting_discovery_ids\": [6, 7, 8, 9]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [12, 14, 18]},\n      {\"term_id\": \"R-HSA-382551\", \"supporting_discovery_ids\": [0, 1, 10]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [2, 20]}\n    ],\n    \"complexes\": [\n      \"α7 homomeric nicotinic acetylcholine receptor\"\n    ],\n    \"partners\": [\n      \"CHRFAM7A\",\n      \"RIC3\",\n      \"NACHO\",\n      \"AP2A1\",\n      \"JAK2\",\n      \"STAT3\",\n      \"YAP1\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}